Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cabaletta Bio (CABA)
NASDAQ:CABA
Holding CABA?
Track your performance easily
CABA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.76 - $26.35
Previous Close$1.87
Volume4.87M
Average Volume (3M)1.17M
Market Cap
$91.40M
Enterprise Value-$76.39M
Total Cash (Recent Filing)$183.01M
Total Debt (Recent Filing)$15.22M
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Mar 13, 2025EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding48,877,164
10 Day Avg. Volume1,670,173
30 Day Avg. Volume1,167,521
Standard Deviation0.39
R-Squared0.10
Alpha0.00951
Financial Highlights & Ratios
Price to Book (P/B)0.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.71
Forecast
1Y Price Target
$18.83Price Target Upside722.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Cabaletta Bio News
PremiumCompany Announcements
Cabaletta Bio Reports Q3 2024 Financial Results
PremiumCompany Announcements
Cabaletta Bio’s Promising Clinical Data on CABA-201
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Patient EnrollmentThe company now has 40 active clinical trial sites, an increase from the 22 reported during its second-quarter earnings, and is continuing to initiate and onboard new clinical sites.
Market ExpansionExpansion into Europe could be utilized in a potential future pivotal trial to augment SLE patient enrollment, which has occurred at a much more rapid pace in Europe than the U.S.
Safety And EfficacyThere was no evidence of ICANS, CRS, infections, or serious adverse events related to the drug.
Bears Say
Clinical Data ConcernsThere appeared to be some investor concern regarding the magnitude of clinical improvement seen in the immune-mediated necrotizing myopathy (IMNM) and lupus patients.
Safety And Financial OverhangThe company's cash position and need for more safety data to allay fears post the Grade 4 ICANS case remain overhangs.
Stock Pressure From Safety IssuesCabaletta's stock is under pressure following the disclosure that one patient among nine dosed in CABA-201's RESET program experienced G4 dose-limiting ICANS.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CABA FAQ
What was Cabaletta Bio’s price range in the past 12 months?
Cabaletta Bio lowest stock price was $1.76 and its highest was $26.35 in the past 12 months.
What is Cabaletta Bio’s market cap?
Currently, no data Available
When is Cabaletta Bio’s upcoming earnings report date?
Cabaletta Bio’s upcoming earnings report date is Mar 13, 2025 which is in 107 days.
How were Cabaletta Bio’s earnings last quarter?
Cabaletta Bio released its earnings results on Nov 14, 2024. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.596 by -$0.024.
Is Cabaletta Bio overvalued?
According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued.
Does Cabaletta Bio pay dividends?
Cabaletta Bio does not currently pay dividends.
What is Cabaletta Bio’s EPS estimate?
Cabaletta Bio’s EPS estimate is -$0.64.
How many shares outstanding does Cabaletta Bio have?
Cabaletta Bio has 48,877,163 shares outstanding.
What happened to Cabaletta Bio’s price movement after its last earnings report?
Cabaletta Bio reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.596. Following the earnings report the stock price went down -5.736%.
Which hedge fund is a major shareholder of Cabaletta Bio?
Among the largest hedge funds holding Cabaletta Bio’s share is Graham Capital Management, L.P.. It holds Cabaletta Bio’s shares valued at 111K.
---
Cabaletta Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.83 (722.27% Upside)
$18.83 (722.27% Upside)
Blogger Sentiment
Bullish
CABA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.85%
12-Months-Change
Fundamentals
Return on Equity
-62.16%
Trailing 12-Months
Asset Growth
17.96%
Trailing 12-Months
Company Description
Cabaletta Bio
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
---
CABA Stock 12 Month Forecast
Average Price Target
$18.83
▲(722.27% Upside)
Technical Analysis
Best Analysts Covering CABA
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+169.40%
reiterated a buy rating 8 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +169.40% per trade.
---